A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-04 and is reviewed periodically as new material appears.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Hoechst stains === Hoechst is a bis-benzimidazole derivative compound that binds to the minor groove of DNA. Often used in fluorescence microscopy for DNA staining, Hoechst stains appear yellow when dissolved in aqueous solutions and emit blue light under UV excitation. There are two major types of Hoechst: Hoechst 33258 and Hoechst 33342. The two compounds are functionally similar, but with a little difference in structure. Hoechst 33258 contains a terminal hydroxyl group and is thus more soluble in aqueous solution, however this characteristics reduces its ability to penetrate the plasma membrane. Hoechst 33342 contains an ethyl substitution on the terminal hydroxyl group (i.e. an ethylether group) making it more hydrophobic for easier plasma membrane passage
=== Onset of symptoms and diagnostic delay === In the classic phenotype, the onset of this disease is usually noticed in childhood, but often not diagnosed until the third or fourth decade of life, frequently due to misdiagnosis and dismissal of symptoms. The median age of symptom onset is 3 years, with the median diagnostic delay being 29 years. Misdiagnosis is overwhelmingly common, with approximately 90% of patients being misdiagnosed, and approximately 62% receiving multiple misdiagnoses before a correct diagnosis. The prolonged diagnostic delay, misdiagnosis or multiple misdiagnoses, or being given inappropriate exercise advice (such as ignore pain or avoid exercise) severely impacts the quality of life (QoL), physically and mentally.
=== Manufacturing === The mechanization and automation of cigarette making is extensive. Since the latter half of the nineteenth century, machinery for rolling and packaging cigarettes has involved many patents and countless person-years of engineering, toolmaking, and millwrighting.
== Specific uses == Affinity chromatography can be used in a number of applications, including nucleic acid purification, protein purification from cell free extracts, and purification from blood. By using affinity chromatography, one can separate proteins that bind to a certain fragment from proteins that do not bind that specific fragment. Because this technique of purification relies on the biological properties of the protein needed, it is a useful technique and proteins can be purified many folds in one step.
Sources: en.wikipedia.org
Many white Southern Christians, including church ministers, attempted to justify their support for slavery as modified by Christian paternalism. The largest denominations, the Baptist, Methodist, and Presbyterian churches, split over the slavery issue into regional organizations of the North and South.
An autograft may also be performed without a solid bony structure, for example, using bone reamed from the anterior superior iliac spine. In this case, there is an osteoinductive and osteogenic action, however, there is no osteoconductive action, as there is no solid bony structure. Chin offers a large amount of cortico-cancellous autograft and easy access among all the intraoral sites. It can be easily harvested in the office settings under local anaesthesia on an outpatient basis. Proximity of the donor and recipient sites reduce operative time and cost. Convenient surgical access, low morbidity, elimination of hospital stay, minimal donor site discomfort and avoidance of cutaneous scars are the added advantages.
=== Further investigations and arrests === Following the verdict, police continued to investigate whether Letby had harmed other infants. Detectives reviewed around 30 cases at the Countess of Chester Hospital that had been identified as "suspicious". Neonatologists examined approximately 4,000 admissions at that hospital, where Letby had worked from 2012, and at Liverpool Women's Hospital, where she had completed two placements in 2012 and 2015, and were asked to refer any "unexpected and unexplained" deteriorations to police. At least one family was informed that their child's case at Liverpool Women's Hospital formed part of the inquiry. Cheshire Police interviewed Letby under caution in relation to deaths at both hospitals. On 2 July 2025, the Crown Prosecution Service confirmed that it was considering further charges based on new evidence provided by the police. On 20 January 2026, after reviewing evidence relating to allegations of murder involving two children and attempted murder involving seven others, the Crown Prosecution Service announced that no further charges would be brought against Letby. On 4 October 2023, Cheshire Constabulary announced an investigation into potential corporate manslaughter at the Countess of Chester Hospital. On 1 July 2025, three members of the hospital's former senior leadership team were arrested on suspicion of gross negligence manslaughter. On 22 April 2026 one of the three was arrested and bailed for perverting the course of justice.
== Human uses == The royal angelfish is considered to be harmless to humans, and has minor commercial use in the aquarium industry. It is valued by aquarium hobbyists for being one of the few "reef safe" angelfish as its diet is composed primarily of sponges, and does not include corals.
=== Regional chains === MEGA MART, Owner by Nongshim JangbogoFoodMart, JangbogoFoodMart is a regional supermarket chain in Korea, focusing on Gyeongsang Province. Owner by JangbogoFoodMart Co, LTD. TopMart, TopMart is a regional supermarket chain in Korea, focusing on Gyeongsang Province. Owner by SEOWON DISTRIBUTION Co., Ltd. TRIAL, TRIAL is Japan Supermarket Chain Group. South Korea Store Owner by TRIAL Korea Co., Ltd. IGA Segyero Mart
Sources: en.wikipedia.org
The feud later affected Fat Joe financially as he sought to secure a $20 million contract endorsing Air Jordan sneakers in early 2005, Michael Jordan himself later cancelled the contract following the VMA incident as he was in fear of conflict with 50 Cent or any other affiliates. Following this, little action was taken between G-Unit or Terror Squad as Fat Joe later admitted to pressuring Irv Gotti to end the feud with G-Unit in 2011, though he was unsuccessful. Jadakiss would end his feud with 50 Cent and G-Unit in 2009 in which he performed together with G-Unit at 50 Cent's ThisIs50 Festival on October 3, 2009. Following his release from jail, DMX sought to make amends with Ja Rule via Irv Gotti, in which the two ended their feud at the 2009 VH1 Hip Hop honors. In May 2011, Ja Rule publicly acknowledged his desire to end the feud, claiming "I'm cool. We ain't beefing no more. We'll never collaborate. That's just what it is. You don't have to be at war with somebody, but it's also kind of like U.S. and another country that they may not get along with. We don't gotta go to war, but we're not friends either. But we can coincide inside of a world. He's doing him, and he's not thinking about me, and I'm doing me and I'm not thinking about him." Following the 2012 death of music executive Chris Lighty a tribute concert was thrown in honor. Both 50 Cent and Fat Joe met prior to the performance and ended their feud out of respect for Lighty. The two rappers would later become business associates and friends following the performance.
Rock salt has been mined at Lake Afrera, and the surrounding part of the Afar Depression, for centuries. Lt. Lefebvre recorded some of the hazards of mining salt from the Depression, which he heard from one of the miners himself:
A ceasefire was reached between Israel and Hezbollah at the end of the 2006 Lebanon War, based on the terms of UN Security Council Resolution 1701 which called for a demilitarized zone between the southern border of Lebanon and the Litani river. The UN Security Council resolution mandated only the Lebanese army and United Nations Interim Force in Lebanon (UNIFIL) could be armed in southern Lebanon. It also stated that neither side should cross the Blue Line, which marks the border between Lebanon and the Golan Heights, and divides the village of Ghajar between the two. Despite this, both Israel and Hezbollah have outstanding obligations under UNSCR 1701. Since 2006, Hezbollah fortified southern Lebanon, obstructed UNIFIL's access, built tunnels into Israel, and crossed the Blue Line. Israel has also accused Hezbollah of using a local environmental organization as a front for its military activities near the Blue Line. After retreating behind the Blue Line in 2000, Israel reoccupied the whole of Ghajar in 2006, including the Lebanese part of the village. Israel continues to occupy Ghajar and an adjacent area, and has repeatedly breached Lebanese airspace, waters, and borders. UNIFIL reports that Israel entered Lebanese airspace on more than 22,000 occasions between 2007 and 2021.
Management of radioactive waste and its safe and secure disposal is a necessary step in the lifecycle of all applications of nuclear science and technology (nuclear energy, research, industry, education, medical, and others). Radioactive waste is therefore generated in practically every country, the largest contribution coming from the nuclear energy lifecycle in countries operating nuclear power plants. Presently, there is broad scientific and technical consensus that disposal of high-level, long-lived radioactive waste in deep geologic formations is, at the state of today’s knowledge, considered as an appropriate and safe means of isolating it from the biosphere for very long time scales.
== Warnings/Precautions == Pancreatitis has been reported in clinical trials, do not continue usage if any pancreatitis has been spotted or confirmed, other therapies should be considered in patients with a prior history of pancreatitis Hypoglycemia has been noted when used in combination with an insulin secretagogue or insulin, consider lowering the usage of insulin in order to reduce the risk of hypoglycemia Hypersensitivity reactions such as anaphylactic reactions and angioedema have occurred; in this case discontinue Trulicity/dulaglutide and seek medical advice Acute kidney injury, monitor the renal function in patients with renal impairment and report severe gastrointestinal reactions Severe gastrointestinal disease, as usage may sometimes be associated with severe gastrointestinal reactions. (Source)
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.